We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Biochemistry and Molecular Biology Hometown: Syracuse, NY Internship Organization: Bryn Mawr College Internship Title: Summer ...

The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) ...

The company is currently developing Diazoxide Choline Extended-Release (DCCR), a tablet that treats Prader-Willi Syndrome (PWS), a genetic disorder. The drug has already completed its phase 3 trials ...

The company is currently developing Diazoxide Choline Extended-Release (DCCR), a tablet that treats Prader-Willi Syndrome (PWS), a genetic disorder. The drug has already completed its phase 3 ...

On Tuesday, the biopharmaceutical company said the U.S. Food and Drug Administration found no apparent need for an advisory committee meeting at this time for Soleno's application for DCCR, or ...

Soleno Therapeutics (NASDAQ:SLNO) is a biotech company that focuses on rare diseases, particularly Prader-Willi Syndrome (PWS) hyperphagia. PWS is a genetic condition that creates insatiable ...

Shares of Soleno Therapeutics gained after regulators decided not to hold an advisory committee meeting over a new drug application for its treatment for Prader-Willi syndrome. The stock was up 16 ...

Mum-of-five Katie Price says son Harvey, 22, needs a little support with his walking and after cane training, his very own ...

For these reasons, and others, Australian sociologist Judy Singer, who coined the phrase neurodiversity, wanted the narrative ...

This is a new drug application (NDA) for the company's diazoxide choline (DCCR) tablets aimed at the treatment of genetic disorder Prader-Willi Syndrome. Soleno isn't entirely in the clear to skip ...